Notice: Undefined index: action in /home/impactinvesting/public_html/wp-content/themes/voice-child/functions.php on line 2
Wells Fargo Adjusts Omnicell Price Target to $39 From $56, Maintains Underweight Rating – Impact investing
10. REDUCED INEQUALITIES

Wells Fargo Adjusts Omnicell Price Target to $39 From $56, Maintains Underweight Rating

Written by Amanda

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. The Company’s point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility’s in-house information management systems. The Company’s Central Pharmacy IV Compounding Service offers a range of service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

More about the company

Source: marketscreener.com

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. The Company’s point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility’s in-house information management systems. The Company’s Central Pharmacy IV Compounding Service offers a range of service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

More about the company

Source: marketscreener.com

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment